Trial to Assess Insulin Detemir's Effect in Combination with Liraglutide and Metformin for Type 2 Diabetes

Type 2 Diabetes (T2D) is a progressive metabolic disorder characterized by insulin resistance and pancreatic beta-cell dysfunction, leading to hyperglycemia. Current management often involves a multi-drug approach, starting with metformin to reduce hepatic glucose production. As the disease progresses, agents like liraglutide, a glucagon-like peptide-1 receptor (GLP-1R) agonist, are introduced to enhance glucose-dependent insulin secretion, suppress glucagon, and promote satiety. Basal insulins, such as insulin detemir, a long-acting insulin analog, are typically added when oral agents and GLP-1R agonists are insufficient to achieve glycemic targets. Optimizing the sequence and combination of these therapies is crucial for effective glycemic control, minimizing side effects, and improving long-term patient outcomes, addressing the persistent challenge of achieving individualized treatment goals in T2D.

This clinical trial, conducted across sites in Europe and North America, was designed to assess and compare the therapeutic effects of a triple combination therapy against a dual therapy in subjects with Type 2 Diabetes. The intervention arm received insulin detemir in combination with liraglutide and metformin. The comparator arm received liraglutide and metformin alone. A key aspect of the study design was that all enrolled subjects continued their pre-trial metformin treatment throughout the duration of the study, ensuring a consistent foundational therapy. The primary objective was to evaluate the comparative "effect" of adding insulin detemir to an existing liraglutide and metformin regimen, though specific endpoints like HbA1c reduction or weight change were not detailed in the abstract.